Novo Nordisk

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments.

CEO

Lars Fruergaard Jørgensen

CEOLars Fruergaard Jørgensen

Employees

76,302

Employees76,302

Headquarters

Bagsværd, Capital Region

HeadquartersBagsværd, Capital Region

Founded

1931

Founded1931

Employees

76,302

Employees76,302

NVO Key Statistics

Market cap

298.17B

Market cap298.17B

Price-Earnings ratio

20.75

Price-Earnings ratio20.75

Dividend yield

1.68%

Dividend yield1.68%

Average volume

6.93M

Average volume6.93M

High today

$69.40

High today$69.40

Low today

$66.92

Low today$66.92

Open price

$68.34

Open price$68.34

Volume

8.82M

Volume8.82M

52 Week high

$148.15

52 Week high$148.15

52 Week low

$66.88

52 Week low$66.88

NVO News

Seeking Alpha 14h

Novo Nordisk's head of commercial strategy Camilla Sylvest steps down

Novo Nordisk (NVO) said Thursday Camilla Sylvest has decided to leave the company, after a distinguished career of 28 years with the drugmaker, seven years as e...

Sherwood News 1d

Trump's tariffs on pharmaceuticals put companies and consumers in uncharted waters

President Trump's tariffs are poised to impact the pharmaceutical industry despite longstanding norms that have insulated the industry — and consumers — from tr...

Quartz 1d

Novo Holdings' earnings nearly doubled in 2024, despite Novo Nordisk's stock slump

Novo Holdings, the controlling shareholder of Ozempic-maker Novo Nordisk (NVO), nearly doubled its annual income and investment returns in 2024. The life scien...

Analyst ratings

66%

of 35 ratings

Buy

65.7%

Hold

28.6%

Sell

5.7%

More NVO News

Benzinga 1d

Novo Nordisk Stakeholder Reports $9 Billion In Income Due To Robust Weight Loss Drug Sales

Novo Holdings, the controlling shareholder of weight loss drugmaker Novo Nordisk A/S NVO, reported Wednesday income and investment returns of 60 billion Danish...

Quartz 2d

Here's how much Ozempic and similar drugs have soared in popularity since 2018

The use of GLP-1 meds — made popular by Ozempic (NVO) — among U.S. adults without diabetes more than tripled between 2018 and 2022, with annual spending surging...

Quartz 3d

Eli Lilly and Novo Nordisk are tackling heart health next

After revolutionizing the weight-loss drug market, Novo Nordisk (NVO) and Eli Lilly (LLY) are setting their sights on heart health. Both pharma giants unveiled...

TipRanks 3d

Novo Nordisk’s Market Leadership Bolstered by Strong Product Data and Promising Future Assets

In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Novo Nordisk (NVO – Research Report), with a price target of $105.00....

TipRanks 4d

Novo Nordisk presents results from STRIDE study on Ozempic

Novo Nordisk (NVO) presented results from STRIDE, its phase 3b trial investigating the effects of once-weekly Ozempic injection 1 mg in adults with type 2 diabe...

TipRanks 6d

Novo Nordisk Stock Slips as Company Defends Weight Loss Drug Candidate

We know that the weight loss drug market has been downright explosive lately, but for drugmaker Novo Nordisk (NVO), it is starting to show signs of decline. The...

Benzinga 6d

Penny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo Nordisk

Lexicon Pharmaceuticals Inc. LXRX stock is trading higher on Friday. Penny stock Lexicon Pharmaceuticals entered into an exclusive license agreement with Novo...